Keytruda has been approved for high-risk early-stage and metastatic triple-negative breast cancer for select patients who are at a high risk of recurrence. Also, the first immunotherapy approved for the adjuvant treatment of certain patients with renal cell carcinoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment